CAR-T-cell treatment designed for several different targets—including epithelial cell adhesion molecule (EpCAM), human epidermal growth factor receptor 2 (HER2), mesothelin, and carcinoembryonic antigen (CEA) in GC—has proven useful in experimental studies, and is currently being evaluated in registered clinical trials including patients with advanced GC [106]. Here, ERBB2 is linked to gastric cancer.